A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies
NCT ID: NCT01013818
Last Updated: 2013-08-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
11 participants
INTERVENTIONAL
2009-10-31
2011-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HGS1029
HGS1029
HGS1029 will be given as a 15-minute IV infusion (in the vein) once weekly for 3 consecutive weeks, followed by 1 week off.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HGS1029
HGS1029 will be given as a 15-minute IV infusion (in the vein) once weekly for 3 consecutive weeks, followed by 1 week off.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Previously treated with at least 2 therapeutic regimens
* ECOG performance \< 2.
* Life expectancy of at least 3 months
* Adequate renal function
* Adequate hematologic status
* Adequate liver function
* Transfusion independent
Exclusion Criteria
* The use of systemic corticosteroids within 1 week of starting treatment with HGS1029
* Evidence of active bacterial, viral or fungal infection within 2 weeks before starting treatment with HGS1029
* Known HIV infection
* Positive for hepatitis B surface antigen or positive hepatitis C antibody
* Grade 2 or greater neuropathy
* Pregnant female or nursing mother
* Males or females who do not agree to use effective contraception during the study and through at least 30 days after the last dose of HGS1029
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Human Genome Sciences Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic
Rochester, Minnesota, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
Oxford Cancer and Haematology Centre
Headington, Oxford, United Kingdom
The Institute of Cancer Research
Belmont, Sutton, Surrey, , United Kingdom
Cancer Research UK Centre
Southampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HGS1029-C1080
Identifier Type: -
Identifier Source: org_study_id